You have 9 free searches left this month | to do more

ibrutinib

Ibrutinib is a drug used to treat Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, and other conditions. Ibrutinib is being actively studied in 153 studies and prior, has been studied in 66.

Top SponsorsTop SitesTop Investigators
Pharmacyclics LLC.Ohio State University Comprehensive Cancer CenterJennifer Woyach
National Cancer Institute (NCI)Memorial Sloan Kettering Cancer CenterBrian Jonas
M.D. Anderson Cancer CenterM D Anderson Cancer CenterKerry Rogers
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
O
Recruiting
  • Chronic Lymphocytic Leukemia
  • Ibrutinib Resistance
  • Ibrutinib
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-10-29
Oct 29, 2021
K
Withdrawn
  • Chronic Lymphocytic Leukemia
  • Loss of Chromosome 17p
  • (no location specified)
2021-10-29
Oct 29, 2021
J
Active, not recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Mantle-Cell
  • Ibrutinib
  • Paris Cedex 13, France
    (unnamed)
2022-03-24
Mar 24, 2022
S
Active, not recruiting
  • Relapsed/Refractory Chronic Lymphocytic Leukemia
  • +2 more
  • Aarau, Switzerland
  • +10 more
2022-03-10
Mar 10, 2022
N
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • La Jolla, California
  • +4 more
2021-12-03
Dec 3, 2021
C
Recruiting
  • Glioblastoma
  • Ibrutinib
  • +2 more
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
2022-01-07
Jan 7, 2022
T
Recruiting
  • Ependymoma
  • +3 more
  • Ibrutinib
  • +3 more
  • Augusta, Georgia
    Augusta University, Georgia Cancer Center
2022-03-20
Mar 20, 2022
C
Recruiting
  • Waldenstrom Macroglobulinemia
  • Carfilzomib + Ibrutinib
  • Ibrutinib
  • Salzburg, Austria
  • +16 more
2022-03-11
Mar 11, 2022
D
Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • MYD88 Gene Mutation
  • Boston, Massachusetts
  • +1 more
2022-04-01
Apr 1, 2022
D
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-09-08
Sep 8, 2021
W
Recruiting
  • Waldenstrom Macroglobulinemia
  • +6 more
  • New York, New York
    Weill Cornell Medicine
2021-12-21
Dec 21, 2021
J
Recruiting
  • Chronic Lymphocytic Leukemia
  • Daratumumab
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-02-24
Feb 24, 2022
U
Completed
  • Metastatic Renal Cell Cancer
  • Stage IV Renal Cell Cancer
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2022-02-08
Feb 8, 2022
N
Recruiting
  • Graft Vs Host Disease
  • Atlanta, Georgia
    Northside Hospital
2022-04-04
Apr 4, 2022
N
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-03-01
Mar 1, 2022
U
Completed
  • Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
  • Ibrutinib
  • Cologne, Germany
    1st Department of Medicine, Cologne University Hospital
2021-04-06
Apr 6, 2021
U
Active, not recruiting
  • Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
  • Refractory Transformed B-cell Non-Hodgkin Lymphoma
  • Ibrutinib
  • Laboratory Biomarker Analysis
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-01-20
Jan 20, 2022
L
Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • (no location specified)
2022-02-15
Feb 15, 2022
M
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • La Jolla, California
    UC San Diego Moores Cancer Center
2021-05-06
May 6, 2021
N
Recruiting
  • Chronic GVHD
  • Ibrutinib
  • Bethesda, Maryland
  • +1 more
2022-04-07
Apr 7, 2022
M
Recruiting
  • T-cell Lymphoma
  • Relapsed and Refractory T-cell Lymphoma
  • Ibrutinib
  • New York, New York
  • +1 more
2021-11-08
Nov 8, 2021
G
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Ibrutinib
  • Placebo
  • Cologne, Germany
    German CLL Study Group
2021-12-16
Dec 16, 2021
M
Recruiting
  • Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
  • +2 more
  • Ibrutinib
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2021-10-29
Oct 29, 2021